Nebu-Flow, a nebulizer platform provider situated in Glasgow, Scotland, UK, has secured an extra $5.9 million in investment.
SCVC led the round, with participation from Ascension, Scottish Enterprise, Foresight WAE Technology, SIS Ventures, and Conduit EIS Impact Fund.
The money will be used by the business to expedite the creation of inhaled medications for those suffering from respiratory conditions.
Under the direction of Drs. Elijah Nazarzadeh (CEO) and John Pritchard (Chairman), Nebu-Flow is creating a new line of nebulizers that will make it possible to administer treatments by inhalation.
“Our mission is to revolutionize respiratory drug delivery,” in response to the news. Our development efforts to position the business for inhalation administration of RNA-based formulations are accelerated by this funding. With the help of SCVC and our other investors, we are now looking forward to the latter phases of product development and commercialization.”
CEO Elijah Nazarzadeh
Other projects:
- The national innovation agency of the United Kingdom, Innovate UK, has granted Nebu-Flow a £1 million project.
- The University of Glasgow spinout was recognized last year by the Institute of Physics for “exceptional efforts in the application of surface acoustic waves to a new generation of nebulizers with the potential to transform respiratory drug delivery” and received the Business Start-up Award.
- Nebu-Flow will be on display at the Respiratory Drug Delivery Conference (RDD 2024), which will take place in Tucson, Arizona, from May 5–9.
About Nebu-Flow:
Developer of a novel pulmonary drug-delivery technology designed for patients with respiratory disorders. The company’s technology enables efficient delivery of hard-to-nebulize drugs to the lungs, including existing formulations and emerging novel therapeutics such as biologics, nanomedicines and vaccines, enabling medical professionals to cure respiratory diseases.